Open AccessP889: WILL OUTCOME IMPROVE BY TREATING MULTIPLE MYELOMA PATIENTS AT MRD RELAPSE? THE REMNANT STUDY (RELAPSE FROM MRD NEGATIVITY AS INDICATION FOR TREATMENT)
Author(s) -
Askeland F. B.,
Rasmussen A.M.,
Lysen A.,
Haukås E.,
Eilertsen A.,
Moksnes M.,
Tsykunova G.,
Vik A.,
Eiken B. D.,
Sørbø J. H.,
Rolke J.,
Sand K. O.,
Hallstensen R. F.,
Myrseth L.,
Slørdahl T. S.,
Schjesvold F.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000846432.28047.c0
Subject(s) - medicine , lenalidomide , oncology , multiple myeloma , bortezomib , minimal residual disease , autologous stem cell transplantation , transplantation , surgery , bone marrow